A multi-center clinical trial is now enrolling patients to test whether surgically implanted electrodes delivering continuous electrical pulses to a specific brain region can relieve depression that has resisted every other available treatment. The study, known as TRANSCEND, represents the largest randomized, sham-controlled trial of deep brain stimulation for this purpose, and it arrives after years of mixed results that have left researchers debating whether the approach works or whether earlier trials simply asked the wrong questions.
Why Standard Treatments Fall Short for Millions
Major depressive disorder ranks among the leading causes of disability worldwide, affecting nearly 200 million people. Most patients respond to some combination of medication, psychotherapy, or newer options like ketamine infusions and transcranial magnetic stimulation. But a stubborn subset, often estimated at roughly one-third of those diagnosed, cycles through treatment after treatment without lasting relief. For these patients, the consequences extend well beyond persistent sadness: elevated suicide risk, inability to work, and years lost to a condition that conventional medicine cannot adequately address.
That gap is what makes deep brain stimulation, or DBS, an appealing if radical option. The procedure, already FDA-approved for movement disorders like Parkinson’s disease, involves implanting thin electrodes into targeted brain structures and connecting them to a battery-powered pulse generator placed under the skin near the collarbone. The device sends continuous electrical signals that modulate neural circuits. Applying this technology to depression, however, requires a different kind of evidence, and the field has struggled to produce it in controlled settings.
A Setback That Reshaped the Field
The central challenge for DBS in depression traces back to a multicenter randomized trial that targeted the subcallosal cingulate, a small region beneath the front of the brain consistently linked to sadness and antidepressant response in imaging studies. That study enrolled 20 patients and found that DBS was safe and feasible but showed no statistically significant antidepressant effect at six months compared to sham stimulation. The result effectively stalled commercial development for years and prompted some to question whether the entire strategy of modulating this region was flawed.
Yet many researchers who worked on that study and its predecessors argue the trial’s design, not the therapy itself, was the problem. Six months may simply be too short a window to detect meaningful change in a condition as deeply entrenched as treatment-resistant depression. The blinded period was brief, the sample was small, and the field lacked tools to verify whether electrodes were hitting the right neural fibers in each patient. Without those tools, stimulation parameters may have been suboptimal or inconsistent across sites. These limitations have driven a wholesale rethinking of how to test DBS for psychiatric conditions, with an emphasis on longer follow-up and more individualized targeting.
Long-Term Data Tells a Different Story
When researchers followed patients for longer periods, the picture shifted considerably. A pooled analysis of 172 patients across multiple subcallosal cingulate DBS cohorts reported meaningful reductions in depression severity scores on the Montgomery–Åsberg Depression Rating Scale at both 12 and 24 months, along with response and partial response rates that improved over time. Importantly, many participants had remained severely ill for years before surgery, suggesting that the observed gains were unlikely to reflect spontaneous recovery.
Separately, a long-term follow-up of individuals receiving subcallosal cingulate stimulation documented durable responses and manageable safety signals well beyond the initial treatment phase. In that cohort, a substantial fraction of patients maintained clinical benefit for several years, with some able to reduce or simplify their medication regimens under supervision. Adverse events related to the hardware or surgery occurred but were generally treatable, reinforcing the view that DBS can be delivered safely in experienced centers.
This pattern, where benefits emerge gradually and strengthen over months or years, sets DBS apart from most psychiatric treatments. Antidepressants typically show their effect within weeks; if they have not worked by two months, clinicians move on. DBS appears to operate on a slower timeline, potentially because it is reshaping neural circuits rather than simply adjusting neurotransmitter levels. That distinction matters for trial design: a six-month blinded comparison may catch the therapy before its full effect materializes, underestimating the true potential benefit for those willing to commit to a long-term intervention.
The TRANSCEND Trial’s Design Choices
The TRANSCEND protocol directly addresses the shortcomings of earlier studies. Registered as NCT06423430, it is a randomized, sham-controlled study that targets the subcallosal cingulate network, the same region implicated in prior work but now approached with more precise targeting methods that use advanced imaging and tractography. Emory University is among the major academic centers enrolling patients, and the trial uses Abbott’s DBS system, a platform already familiar to neurosurgeons treating movement disorders.
Eligible participants must have endured multiple failed treatments and carry severe symptom burdens, ensuring the study focuses on people for whom existing options have genuinely been exhausted. The trial’s structure reflects lessons learned from past disappointments. By extending the blinded comparison period and planning an open-label extension phase, investigators aim to capture the delayed treatment effects that earlier trials may have missed. Patients randomized to sham stimulation receive implanted devices that are not activated initially, allowing researchers to parse out the impact of surgery and expectation from the effect of active current.
The use of sham controls remains ethically complex but scientifically necessary. Without a rigorous comparison group, any improvement could be attributed to the placebo effect of undergoing brain surgery, a phenomenon well documented in neurostimulation research. To mitigate ethical concerns, the sham phase is time-limited, and all participants ultimately gain access to active stimulation if they remain in the study. The investigators also build in close monitoring, with clear protocols for addressing worsening symptoms or emergent suicidal risk.
Brain Biomarkers Could Change How DBS Is Delivered
One of the most significant recent advances involves recording brain activity directly from implanted DBS electrodes to identify neural signatures that track with recovery. Research published in Nature used longitudinal analysis of patients receiving subcallosal cingulate DBS to identify cingulate dynamics that correlated with symptom improvement over time. These patterns, detected as patients moved from severe depression toward partial or full response, suggest that specific oscillatory changes in this network may serve as objective markers of therapeutic progress.
The work was supported in part by the NIH BRAIN Initiative, and a federal summary highlighted the potential of such biomarkers to guide stimulation settings in real time. If clinicians can reliably measure when a patient’s brain circuits are shifting toward a healthier state, they may be able to fine-tune voltage, pulse width, or frequency more efficiently than by relying on symptom reports alone. This approach mirrors the evolution of DBS for movement disorders, where sensing-enabled devices now help optimize therapy by tracking abnormal motor rhythms.
Parallel efforts are focused on tailoring treatment to individual brain wiring. A National Institute of Mental Health update on personalizing stimulation describes how structural connectivity maps can predict which patients are most likely to respond when electrodes are placed along specific fiber pathways. In practice, this means that two people with the same clinical diagnosis might receive slightly different targeting strategies, based on the organization of their white matter tracts and the networks most responsible for their symptoms.
TRANSCEND incorporates these insights by emphasizing connectivity-informed implantation and systematic collection of neural recordings where possible. Over time, the hope is that pooled data from this and related studies will clarify which biomarkers best forecast durable response, and how early in the course of treatment they can be detected. Such knowledge could reduce the trial-and-error period after surgery and help identify nonresponders sooner, sparing them months of ineffective adjustment.
Balancing Hope, Risk, and Uncertainty
For patients and families confronting years of unrelenting depression, the prospect of a brain implant that might restore function is both compelling and daunting. DBS is invasive, expensive, and not without risk; it demands a lifelong relationship with a specialized care team and regular device maintenance. Yet for those who have exhausted medications, psychotherapy, and noninvasive neuromodulation, the alternative is often continued suffering with little realistic prospect of change.
The TRANSCEND trial will not settle every question about deep brain stimulation for depression, but its scale, design, and incorporation of modern neurotechnology make it a pivotal test. If the results confirm the long-term observational data, DBS could move closer to a defined role as a last-line option for the most severe, treatment-resistant cases. If they do not, the field will need to confront whether different targets, stimulation paradigms, or entirely new strategies are required.
Either way, the effort reflects a broader shift in psychiatry toward circuit-based interventions informed by objective brain measurements. For a disorder that has long been diagnosed and treated solely through symptoms, the convergence of imaging, electrophysiology, and personalized neuromodulation offers a rare chance to rethink what effective care might look like when standard approaches are no longer enough.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
